Stay updated on LN-145 & Durvalumab Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page.

Latest updates to the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page
- Check3 days agoChange DetectedAdded a government funding notice banner and updated the page version to v3.4.1 (removing v3.4.0). The changes appear cosmetic and do not modify the study details, eligibility criteria, or outcomes.SummaryDifference0.4%

- Check10 days agoChange DetectedNon-substantive UI and wording updates include adding a glossary toggle and minor capitalization changes to QC-related metadata and the revision label. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 is now displayed on the page. This is a minor metadata update and does not modify the study details, eligibility criteria, or user actions.SummaryDifference0.1%

- Check45 days agoChange DetectedAdded a dedicated Locations section listing California, Kentucky, Michigan, New Jersey, Pennsylvania, Tennessee, and Washington, plus a new revision note (v3.3.3). Removed the individual state location subsections (California Locations, Kentucky Locations, etc.) and the previous revision note (v3.3.2).SummaryDifference0.9%

- Check73 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no changes to study details, eligibility criteria, locations, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange Detected- Removed the government funding/operational status banner; the study details, eligibility criteria, and locations remain unchanged.SummaryDifference0.4%

Stay in the know with updates to LN-145 & Durvalumab Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 & Durvalumab Combo in NSCLC Clinical Trial page.